DOCSLIB.ORG

Innovation: Strategy, Successes and Challenges

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Innovation: Strategy, Successes and Challenges Innovation: Strategy, Successes and Challenges Presentation to Research Administrators Discussion Group April 14, 2016 Christopher Coburn Vice President, Innovation PHS Strategies to Enhance Revenues from Industry & Commercialization • Create an integrated “front door” for industry – Streamline contracting process, enhance efficiency – Expand IRB services: agreements with commercial IRBs, focus on improving turn-around-times • Launch a Clinical Trials Office – Establish clinical trials office, with close ties to CCI (BWH), CRP (MGH), McLean, and Spaulding • Leverage key Partners investments – eCare – Big Data Commons – creating commercialization opportunities w/Big Data initiatives and analytics (e.g., integrating siloed datasets: phenotyping, imaging, genetics/genomic, etc.) – PHS Biobank Innovation Confidential – do not copy or distribute 2 Operating Thesis • As largest academic research enterprise, PHS has unrivaled potential. If it: – better organizes its enormous capabilities, – actively leverages its strategic assets, – more effectively engages industry, – better exploits its prized Boston home, – increases its “innovation brand” and – runs Innovation like a business . • . it can derive significantly greater financial and patient benefits from the creativity of its clinical, research and administrative staff and its organizational standing Innovation Confidential – do not copy or distribute 3 Revenue Growth Revenue Growth $140 ($M) $120 $100 $80 $60 $40 $20 $0 FY13 FY14 FY15 FY16 FY17 FY18 Innovation Confidential – do not copy or distribute 4 Increased Potential Research ($B) Active IP Applications $2.0 800 $1.5 600 $1.0 400 $0.5 200 0 $0.0 2011 2012 2013 2014 2015 2007 2015 80 Innovation FTEs (budget) Investigators 4000 60 3000 40 2000 20 1000 0 0 2011 2012 2013 2014 2015 FY13 FY14 FY15 Innovation Confidential – do not copy or distribute 5 Market Sectors Cancer & Dermatology Anesthesia Neuroscience Radiology Cardiovascular Medicine & Surgery Orthopedics Business Venture Pathology & Plastics & Pulmonology Pediatrics Rheumatology Development Regen Medicine . Market Sector Pat Fortune, PhD Jon Behr, PhD Sepi Hashemi Leader Phil Trung Roger Licari Do Kitterman Carl Berke, PhD Director Dan Castro Jim Roberts Emy Chen, PhD Seema Basu, PhD Nancy Lugn Meredith Fisher PhD Jay Knowles Revenue Goal $13M $23M $2M $3M $3M $1M $6M $1M $33M $9M $5M $103M* Invention Goal 550 87 71 34 79 85 38 81 53 22 License Goal 31 16 10 53 22 8 47 13 12 212 Research Volume* $1.5B* $300M $60M $42M $266M $94M $102M $445M $75M $62M TRIALS $50M $3M $4M $41M $6M $20M $161M $1M $7M FTE Count 4 2 2 3 3 2 2 1 3 3 3 • Clinical “verticals” with senior industry executive leading each Sector • Unique strategy set in each • Deep domain knowledge; hospital leadership engaged by Department • Cohesive, tailored offerings to industry • Industry perspectives to faculty by Sector • Industry workflow expert leading operations Innovation Confidential – do not copy or distribute 6 Innovation Advisory Board Duke Collier Paul LaViolette Joe Cunningham, MD Neil Exter Jean-François Formela, MD Adele Gulfo IAB Chair IAB Vice Chair, Santé Ventures Third Rock Ventures Atlas Ventures EVP, Mylan SV Life Sciences Michael Greeley Steve Gullans, PhD Andy Hurd Ed Kania Keith Kerman, MD Barbara Lubash Flare Capital Partners Excel Ventures CEO, MedeAnalytics Flagship Ventures Riverside Company Versant Ventures Amir Nashat, PhD Steve Oesterle, MD Ben Pless Russ Richmond, MD, Sue Siegel Steve Weinstein Polaris Ventures NEA CEO, CEO, Advanced GE Ventures Novartis Ventures Autonomic Technologies Practice Strategies Innovation Confidential – do not copy or distribute 7 Working With Innovation: Cancer/Pathology Market Sector Cancer/Pathology Capabilities Invention/Discovery, IP Protection, Licensing, Industry Sponsored Research Patrick Fortune PhD Daniel Castro Senior Market Sector Leader Director, Business Strategy and Licensing 857-307-2473 857-307-2470 Innovation Confidential – do not copy or distribute 8 Working With Innovation: Cardiovascular Market Sector Cardiovascular Capabilities Invention/Discovery, IP Protection, Licensing, Industry Sponsored Research Sepideh Hashemi Jacob Pierson Market Sector Leader and EIR Licensing Manager 857-307-2444 857-307-2446 Innovation Confidential – do not copy or distribute 9 Individual Process Contact your Our team works We provide LM with you Unmet IP: Models for collaboration need/Problem you Is it novel, has are trying to solve utility non obvious? Patent strategy, filing and licensing What is the proposed Market: Agreements product/service? Is there interested partner to sponsor Facilitation with PIF research or develop Connection to Trial Office 1 week 4-8 weeks Depends on external collaborator Innovation Confidential – do not copy or distribute 10 1 Operating Model Care Path Novel Unmet Needs Disease Insights Integration/ Intervention Optimization Market Sectors: Market Pull with Technology Push Triage Well Value Catalyze Unmet Need Proposition/ • Manage Assets & Idea Generation Translation Connect to • Relationships Potential/Leverage Funding Deliver Tangible Value Engage with Other Areas • Relationship Division IP Protection • Diverse/current/broad • – Investigators • Leaders Outlook Set IP Patent Portfolio • – Industry Cultivate – FDA approval Strategy Compelling SRA • – Investors • Connections – Adoption Strategic Alliances IP/FTO • Identify/ – Reimbursement • Thriving Spin-offs • Innovation Team and • nurture Partnership • Digitally-Enabled Care • Tactical Program • prolific Potential Effective Management innovators – Industry Development – Investors – Foundations Innovation Confidential – do not copy or distribute 11 The Full Package The problem that you are trying to solve The solution and benefits (ex: reduce x/improve y, both clinical and economic) The offering (What is the product, platform or service?) Proof points (Data that is already available that validates the hypothesis, results presented (?) and publication in progress (?),physician affiliations (institutions) interested in early involvement, animal models that are highly relevant Stage of IP (Pending application covering XXX, IP portfolio overview) Management team (Names, years of cumulative healthcare, clinical and start-up experience); envisioned teams for regulatory, IP support. Market opportunity worldwide (Scale of problem, immediate market , market expansion, envisioned risks to market development and physician adoption) Market opportunity US Possible other related projects for the company Competition/Competitive landscape: Are there other companies working to develop such a device, compound, diagnostic or service? Any even addressing the problem, what are they, advantages and disadvantages of existing therapies. What is the competitive advantage that this solution will offer? Healthcare Economics: Understanding of opportunities and barriers to adoption Regulatory If you are aware of current FDA guidelines Development plan with Timeline Phases to develop, Key milestones, Time to market Exit plan Aiming for $X: Acquisition by a strategic partner What is the ask XX dollars to fund ABC Innovation Confidential – do not copy or distribute 12 Partners Innovation Fund - $100M Fund I $35M (2007), 25 companies -> $100M (2016) Portfolio enterprise value >$2.2B 5 exits, 26%IRR, $23M returned Adheron Anti-Cad-11 antibodies for treatment of RA, NASH, other indications Acquired by Roche in October 2015 for $580 million Annovation Safer anesthetic agent Acquired by Medicines Company February 2015 CoStim Pharmaceuticals Cancer immunotherapeutics around TIM-3 Acquired by Novartis in February 2014 Editas Company IPO in 2016 8.5x return; Market Cap >$1B QPID Health Acquired by eviCore February 2016 Fund II raises total to $100M Innovation Confidential – do not copy or distribute 13 113 PHS Spin-offs in MA (203 WW) Licensed Technology Alchimist Cambridge Devices, Inc. Alito Scientific Inc. Canthera Therapeutics Alopexx Pharmaceuticals Cerebrotec Alopexx Vaccines Chylack Incorporated Amasa Technologies Inc Colonary Concepts American Xeno, Inc. Commissure Inc. Annovation Biopharma CoStim ARGIL Imaging Cytocure LLC Avekshan LLC Deltix AviTx Inc. Descartes Therapeutics AZ Therapies Diacrin, Inc. BIND Therapeutics Empathetics, LLC BioEngine EndoLumina Solutions Biomodels, LLC eNOS Pharmaceuticals BioTransplant Inc. Epix Pharmaceuticals, Inc. Bixzen Therapeutics Functional Pharmaceuticals Gamete Technology, Inc. Ra Pharmaceuticals, Inc. General Fluidics RaNA Therapeutics, Inc. GI Company Raze Therapeutics HanGenix Renalworks Medical Harmonie Group, Inc. Riparian Pharmaceuticals Health Image, LLC RSTAR Inanovate, Inc. Sentien Biotechnologies, Inc. Investors Bio-Tech, Ltd. ShiftWork Systems, Inc. Lysosomal Therapeutics Sirtris Pharmaceuticals, Inc. MegaCell Therapeutics Solace Pharmaceuticals, Inc. Mercury Therapeutics, Inc. Spero Therapeutics MiRTLE Medical, LLC Synostics Inc. Equity Ownership Molecular Insight Syntonix Pharmaceuticals ArcherDx Hepregen Provasculon MoMelan T2 Biosystems, Inc. Ascelegen Therapeutics ImmuneXcite QPID Health Neuroptix Tal Medical Blend Therapeutics KDAC Therapeutics Quartet Medicine NinePoint Medical Teleos Pharmaceuticals Combinent BioMedical Life Image Rodin Therapeutics NitroMed, Inc. Tensha Therapeutics Cytrellis Biosystems Link Medicine Selecta Biosciences Nyx Devices Transkaryotic Therapies, Inc Daktari Diagnostics Nanopharma Spero Therapeutics On-Q-ity Vactex, Inc. DecImmune Therapeutics Newton Labs Symbiotix Biotherapies Orthopedic Technology Verinata
Load more

Recommended publications
  • Guardant Health, Inc. Form 8-K Current Event Report Filed 2019-01
    SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2019-01-07 | Period of Report: 2019-01-07 SEC Accession No. 0001628280-19-000132 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 8-K | Act: 34 | File No.: 001-38683 | Film No.: 19512177 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2019 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 0001-576280 45-4139254 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation or organization) File Number) Identification No.) 505 Penobscot Dr. Redwood City, California 94063 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under
    [Show full text]
  • Guardant Health, Inc. Form 10-Q Quarterly Report Filed 2021-08-05
    SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Quarterly report pursuant to sections 13 or 15(d) Filing Date: 2021-08-05 | Period of Report: 2021-06-30 SEC Accession No. 0001576280-21-000080 (HTML Version on secdatabase.com) FILER Guardant Health, Inc. Mailing Address Business Address 505 PENOBSCOT DR. 505 PENOBSCOT DR. CIK:1576280| IRS No.: 454139254 | State of Incorp.:DE | Fiscal Year End: 1231 REDWOOD CITY CA 94063 REDWOOD CITY CA 94063 Type: 10-Q | Act: 34 | File No.: 001-38683 | Film No.: 211148786 855-698-8887 SIC: 8071 Medical laboratories Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ Delaware 45-4139254 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 505 Penobscot Dr. Redwood City, California, 94063 Registrant’s telephone number, including area code: (855) 698-8887 _______________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Monitoring Trace Levels of Ctdna Using Integration of Variant Reads
    Monitoring trace levels of ctDNA using 1 integration of variant reads 2 3 Jonathan C. M. Wan 4 Supervisor: Dr Nitzan Rosenfeld 5 6 Cancer Research UK Cambridge Institute 7 8 University of Cambridge This dissertation is submitted for the degree of 9 Doctor of Philosophy 10 Trinity College May 2019 11 Abstract 12 In patients with early-stage cancer, ctDNA detection rates can be low due to the presence of 13 few or no copies of any individual mutation in each sample. Sensitivity may be increased 14 by collecting larger plasma volumes, but this is not feasible in practice. Although cancers 15 typically have thousands of mutations in their genome, previous analyses measured only 16 individual or up to 32 tumour-specific mutations in plasma. 17 Here, we demonstrate that sensitivity can be greatly enhanced for any given input DNA 18 mass by analysing a large number of mutations via sequencing. We sequenced in plasma 2 4 19 10 -10 mutated loci per patient, using custom capture panels, whole exome (WES) or 20 whole genome sequencing (WGS). We developed a method for INtegration of VAriant Reads 21 (INVAR) that aggregates reads carrying tumour mutations across multiple mutant loci, and 22 assigns confidence to error-suppressed reads based on mutation context, fragment length and 23 tumour representation. This workflow combines a number of concepts in a novel approach in 24 order to quantify ctDNA with maximal sensitivity. 25 We applied INVARto plasma sequencing data from 45 patients with stage II-IV melanoma 26 and 26 healthy individuals. ctDNA was detected to 1 mutant molecule per million, and tu- 3 27 mour volumes of ~1cm .
    [Show full text]
  • Liquid Biopsy Is at the Core of Our Mission to Conquer Cancer with Data
    guardanthealth.com • [email protected] • +1.812.731.2203 CORPORATE BACKGROUNDER LIQUID BIOPSY IS AT THE CORE OF OUR MISSION TO CONQUER CANCER WITH DATA Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets, and advanced analytics. A company uniquely positioned to help patients across the entire cancer care continuum At Guardant Health, we believe liquid biopsy is at the center of transforming cancer care by unlocking data that will help patients at all stages of the disease. While we’ve made great strides to help advanced cancer patients, our vision since inception has been to detect cancer early, when patient survival rates can be impacted most. We are dedicated to helping patients across the cancer care continuum live longer, healthier lives. 700K+ 15M+ 65M+ Advanced Cancer Early-Stage Patients Asymptomatic and Patients and Survivors High Risk Screening Guardant360® CDx liquid biopsy LUNAR-1 program (in development) LUNAR-2 program (in development) (Estimated number of patients in the US) Guardant360® CDx liquid biopsy is poised to bring the promise of precision oncology to more patients Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive genomic profiling (CGP) in advanced cancer patients across all solid cancers, and for use as a companion diagnostic for patients who may benefit from Tagrisso® (osimertinib). We believe the ease of our blood test together with approval will help widen adoption of CGP and enable more patients to receive potentially life-changing precision medicines. In 2014, we introduced the Guardant360 laboratory developed test (LDT), the first-in-kind liquid biopsy to comprehensively sequence a patient's cancer to reveal actionable mutations.
    [Show full text]
  • Prospective Blinded Study of Somatic Mutation Detection in Cell-Free DNA Utilizing a Targeted 54-Gene Next Generation Sequencing
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 37 Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Seung Tae Kim1,*, Won-Suk Lee2,*, Richard B. Lanman3, Stefanie Mortimer3, Oliver A. Zill3, Kyoung-Mee Kim4,5, Kee Taek Jang5, Seok-Hyung Kim5, Se Hoon Park1, Joon Oh Park1,4, Young Suk Park1, Ho Yeong Lim1, Helmy Eltoukhy3, Won Ki Kang1, Woo Yong Lee6, Hee-Cheol Kim6, Keunchil Park1,4, Jeeyun Lee1,4, AmirAli Talasaz3 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2 Department of Surgery, Gil Medical Center, Gachon University, School of Medicine, Incheon, Korea 3 Guardant Health Inc., Redwood City, CA, USA 4 The Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Korea 5 Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 6 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea *These authors have contributed equally to this work Correspondence to: Jeeyun Lee, e-mail: [email protected] AmirAli Talasaz, e-mail: [email protected] Keywords: cell-free DNA (cfDNA), digital sequencing, genomic test Received: July 31, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Sequencing of the mutant allele fraction of circulating cell-free DNA (cfDNA) derived from tumors is increasingly utilized to detect actionable genomic alterations in cancer. We conducted a prospective blinded study of a comprehensive cfDNA sequencing panel with 54 cancer genes. To evaluate the concordance between cfDNA and tumor DNA (tDNA), sequencing results were compared between cfDNA from plasma and genomic tumor DNA (tDNA).
    [Show full text]
  • The Top 50 Healthcare Technology Ceos of 2021
    The Top 50 Healthcare Technology CEOs Of 2021 April 14, 2021 The Healthcare Technology Report is pleased to announce the Top 50 Healthcare Technology CEOs of 2021. This year’s awardees represent some of the most accomplished executives in healthcare technology. Their leadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies. Notably, in addition to overseeing their companies’ efforts from the C-suite, many of these leaders were also founders or co-founders of their organizations, recognizing unique opportunities for transformation and growth within their areas of expertise. From inventing novel orthopedic and mobility devices, to spearheading platforms to strengthen the patient/provider connection, and to developing new blood tests to diagnose diseases, these awardees have made significant contributions to society at large. They come from varied backgrounds in medicine, research, biotechnology, business, and finance, leveraging unique insights to provide their companies with the agility and ingenuity needed to thrive. While highly involved and instrumental to the continued success of their companies, they have also remained dedicated to advancing their particular fields, with many participating in prestigious research institutions and trade groups that are collaborating to develop more effective solutions for patients across the globe. Please join us in honoring The Top 50 Healthcare Technology CEOs of 2021. The Healthcare Technology Report https://thehealthcaretechnologyreport.com/the-top-50-healthcare-technology-ceos-of-2021/ 1. Geoff Martha Company: Medtronic Title: Chairman of the Board of Directors and Chief Executive Officer Geoff Martha is Chairman of the Board of Directors and Chief Executive Officer at Medtronic.
    [Show full text]
  • The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California
    The Future of Genomic Medicine IX Thursday, March 3 and Friday, March 4, 2016 • Scripps Institution of Oceanography • La Jolla, California Presented in partnership with AAAS/Science Translational Medicine Course Introduction Conference Highlights • Voice of the patient represented Course Overview throughout the conference In collaboration with AAAS/Science Translational Medicine we invite you to • Renowned faculty representing the another exciting two day program on Thursday, March 3 and Friday, March country’s leading institutions • Multiple panel discussion segments 4, 2016 in beautiful San Diego, California. The 2016 program will again be with ample question and answer time with faculty held at Scripps Institution of Oceanography. • Additional networking opportunities The 9th Future of Genomic Medicine conference will be the next iteration Educational Objectives of taking genomic knowledge to transform the daily practice of medicine. After attending this activity, participants should be able to: To do this, we have patients present their story of how genomics affected • Demonstrate the unmet needs of their medical status, and have an international faculty of experts in genomics, medicine today with respect to more targeted, individualized prevention science and medical journalism, and the life science industry provide critical and treatments. perspective. This year we will be paying particular attention to the exciting • Discuss the opportunities of the genome, proteome, metabolome area of genomic editing to treat particular diseases, cancer (a disease of the discovery to change medical practice as it exists today. genome), and the genomics of rare and unknown diseases. Furthermore, we • Assess how changes and advances in will delve into to the hot topics of the microbiome, genomic-guided drug technology are rapidly ushering in a whole array of new pathways for therapies and genomic analytics.
    [Show full text]
  • Guardant Health Q3 2020 Earnings Call
    Guardant Health Third Quarter 2020 Earnings Call November 5, 2020 Guardant Health – Third Quarter 2020 Earnings Call, November 5, 2020 C O R P O R A T E P A R T I C I P A N T S Carrie Mendivil, Investor Relations - Gilmartin Group Helmy Eltoukhy, Co-founder and Chief Executive Officer AmirAli Talasaz, Co-founder and President Derek Bertocci, Chief Financial Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Puneet Souda, SVB Tycho Peterson, JPMorgan Doug Schenkel, Cowen Derik de Bruin, Bank of America Brian Weinstein, William Blair Patrick Donnelly, Citigroup Tejas Savant, Morgan Stanley Sung Ji Nam, BTIG P R E S E N T A T I O N Operator Ladies and gentlemen, thank you for standing by, and welcome to the Guardant Health Q3 2020 Earnings Call. At this time all participants are in a listen-only-mode. After the speaker’s presentation, there will be a question-and-answer session. To ask a question during the session, you need to press star, one on your telephone. If you wish to withdraw your question, press the pound key. I would now like to turn the conference over to your speaker today, Carrie Mendivil with Investor Relations. You may begin. Carrie Mendivil 1 ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.
    [Show full text]
  • Guardant Steps Into a New Arena
    June 22, 2021 Guardant steps into a new arena Elizabeth Cairns A test that tracks response to therapy is useful, but approval and reimbursement will be key. One of the groups locked in battle for dominance of the pan-cancer blood test market has just pulled ahead in a new setting. Today Guardant Health launched in the US what it claims is the first liquid biopsy that can track a patient’s response to immunotherapy or targeted drugs, and do so more quickly than current methods used by oncologists. Questions remain, notably around pricing and reimbursement. Given that the Guardant360 Response test will have to be administered repeatedly, costs could mount up fast. But the existing approved tumour-agnostic liquid biopsies are seeing increased acceptance, so Guardant360 Response could find a market – though formal FDA approval would probably be a necessary step to get payers on board. Guardant360 Response, launched in the US as a lab-developed test, can pinpoint the levels of circulating tumour DNA (ctDNA) in a patient’s blood; by tracking how these fluctuate it can determine whether the patient is responding to their prescribed drug regimen. This is a different setting from the group’s only FDA-approved test, Guardant360 CDx, which is used to profile a patient’s tumour biomarkers. Guardant360 Response is believed to test for 74 genetic mutations, whereas Guardant360 CDx is more comprehensive. Guardant Health's liquid biopsies Test Setting Status Launched as LDT May Guardant360 Pan-cancer; helps assign targeted therapy 30, 2014 Guardant360 CDx Pan-cancer; helps assign targeted therapy Approved Aug 7, 2020 Guardant360 Launched as LDT Jun Pan-cancer; tracks response to targeted or immunotherapy Response 22, 2021 Guardant360 Pan-cancer tissue test; helps assign targeted therapy – to be Launched as LDT Jun TissueNext* ordered at same time as Guardant360 CDx 22, 2021 Pan-cancer; sold to biopharma companies to aid drug Launched in 2017 for GuardantOMNI development.
    [Show full text]
  • Moneyball Medicine Discusses Some of the Remarkable Innovations That Are Developing Across the Healthcare Industry
    MoneyBall Medicine discusses some of the remarkable innovations that are developing across the healthcare industry. Harry and Malorye provide readers with a front row seat to the most important emerging healthcare system challenges—and opportunities—of our time. We started Flatiron because we wanted to ensure that all cancer patients—not just those with the means and resources—have access to the same cutting-edge research. It is our hope that this book will stimu- late discussions around the value of next-generation technology in healthcare so that the industry can continue to innovate. Zach Weinberg Cofounder, COO, and President Flatiron Health MoneyBall Medicine puts you at the center of healthcare’s new frontier where medicine, tech- nology, information, and business are converging and advancing with unprecedented speed and importance. The stakes could not be higher, and I recommend this book for anyone interested in learning more about this truly disruptive revolution in the ever-changing healthcare landscape. Eric Schadt, PhD Dean for Precision Medicine, Mount Sinai Health System Professor, Genetics and Genomic Sciences at Mount Sinai The political turbulence focused on what comes next for Medicaid, Medicare, and the Affordable Care Act (Obamacare) public exchange products simply reinforces the fundamentals of healthcare in the United States. Increased access, increased value, and better patient experience will be keys for all successful stakeholders. In MoneyBall Medicine, Harry and Malorye describe the unique confluence of entrepreneurial innovation and the many entrenched and evolving healthcare components of the healthcare supply chain, and defines the parameters that predict who will win and who will lose.
    [Show full text]
  • Never Lose Hope Page
    Fertility after cancer treatment P.10-11 Never Lose Hope Six-year-old Jasmine was diagnosed with acute lymphoblastic leukaemia last year. Here, Jasmine’s mum Karen shares her daughter’s story. Page 8-9 Nurse service on the help line now available Monday – Friday. Call Freephone 08088 010 444. SUMMER EDITION 2017 www.leukaemiacare.org.uk In This Issue... P.4 News Catch up on the latest news from our Campaigns and Advocacy team P.7 Kris is WIRED at Executive Health Conference Trustee Kris discovers up and coming treatments for blood cancer at WIRED Health P.10 Fertility after cancer treatment How can treatment affect your fertility? P.12 Karen Orwin’s Story P.8 Read how Karen defied the odds Jasmine’s Story P.13 Fundraising news See what our fundraisers have been up to P.10 Fertility Feature P.14 Radiotherapy - what’s it all about? Learn the ins and outs of radiotherepy P.7 P.16 Clinical trials: what are they? Kris is WIRED Our Nurse Advisor, Angela gives an insight into how clinical trials work P.16 P.18 Clinical Trials Support P.18 Support group spotlight Group Our Liverpool support group has been busy P.19 London Marathon Find out what happened on the big day Hello, P.12 This Summer edition is packed full of informative Karen Orwin’s articles and inspiring patient stories. We have all Story you need to know about clinical trials, as well as a spotlight on our longest running support group. Our Campaigns and Advocacy team are also on hand to update you on the latest news, along with a feature on our new report.
    [Show full text]
  • The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
    Author Manuscript Published OnlineFirst on May 18, 2018; DOI: 10.1158/1078-0432.CCR-17-3837 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients Oliver A. Zill, PhD1,†, Kimberly C. Banks, MS, MBA1, Stephen R. Fairclough, PhD1,*, Stefanie A. Mortimer, PhD1, James V. Vowles, PhD1, Reza Mokhtari, MS1, David R. Gandara, MD2, Philip C. Mack, PhD2, Justin I. Odegaard, MD, PhD1, Rebecca J. Nagy, MS1, Arthur M. Baca, MD, PhD1, Helmy Eltoukhy, PhD1, Darya I. Chudova, PhD1, Richard B. Lanman, MD1, AmirAli Talasaz, PhD1 1 Guardant Health, Inc., Redwood City, CA, 94063, USA. 2 University of California Davis Comprehensive Cancer Center, Sacramento, CA, 95817, USA. † Present address: Department of Bioinformatics and Computational Biology, Genentech, 1 DNA Way, South San Francisco, California 94080, USA. Running title: Somatic genomic landscape of circulating tumor DNA Keywords: circulating tumor DNA, tumor heterogeneity, resistance, genomic landscape, cfDNA clonality Financial support: The study was funded by and conducted at Guardant Health, Inc. No additional grant support or administrative support was provided for the study. *Corresponding author: Stephen R. Fairclough, PhD 505 Penobscot Dr, Redwood City, CA 94063 Email: [email protected] Phone: (855) 698-8887 Conflict of interest statement: All authors except Dr. Mack and Dr. Gandara are paid employees and/or stockholders of Guardant Health, Inc. Dr. Mack has received honoraria from Guardant Health. Dr. Gandara has no financial relationships to disclose. Word count: 4,707 Total number of figures and tables: 6 Downloaded from clincancerres.aacrjournals.org on September 27, 2021.
    [Show full text]